GlassScriptPhysician profile
Dilip B Viswanath
NPI 1528019262
$167,112.94
in general payments reported to CMS, 2019-2025
38 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $30K · 2021: $66K · 2022: $21K · 2023: $9,761 · 2024: $8,549 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,536 · Travel and Lodging: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,874.00 |
| Food and Beverage | $6,535.87 |
| Travel and Lodging | $938.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $85,912.40 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $57,559.80 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $6,507.87 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $5,423.76 | 2021-2025 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $3,008.28 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Abbott Laboratories | $1,009.71 | 2019-2025 | Aveir, Perclose Prostyle, Cardiomems |
| Pfizer INC. | $968.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $945.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.00 | 2019-2025 | Jardiance |
| Biotronik INC. | $743.77 | 2019-2021 | |
| Amgen INC. | $728.16 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $417.14 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $390.34 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $365.42 | 2021-2025 | |
| Boston Scientific Corporation | $364.18 | 2019-2024 | Watchman Flx, Bodyguardian |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $338.61 | 2019-2021 | |
| Medtronic, INC. | $291.49 | 2022-2024 | Pipeline |
| Regeneron Healthcare Solutions, INC. | $276.06 | 2019-2024 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $221.28 | 2019-2021 | |
| Medtronic Vascular, INC. | $202.20 | 2019 | |
| W. L. Gore & Associates, INC. | $159.80 | 2019-2022 | |
| Scpharmaceuticals INC. | $104.75 | 2024-2025 | |
| Biosense Webster, INC. | $52.75 | 2021 | |
| Lundbeck LLC | $52.50 | 2019-2020 | |
| Cvrx, INC. | $52.10 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $44.73 | 2024 | Arcalyst |
| Heartflow, INC. | $37.18 | 2024-2025 | |
| Inspire Medical Systems, INC. | $31.89 | 2024-2025 | Inspire |
| Bridgebio Pharma, INC. | $31.33 | 2025 | Attruby |
| Novo Nordisk INC | $30.87 | 2024-2025 | Wegovy |
| Regeneron Pharmaceuticals, INC. | $16.80 | 2019 | |
| Kestra Medical Technology Services, INC. | $14.35 | 2023 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $13.92 | 2019 | |
| Daiichi Sankyo INC. | $13.86 | 2024 | Injectafer |
| Preventice Services, LLC | $12.78 | 2020 | |
| Gilead Sciences, INC. | $11.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Viswanath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.